Open Research Studies at the Penn Memory Center

The “Risk Evaluation and Education for Alzheimer’s Disease – the Study of Communicating Amyloid Neuroimaging” study (REVEAL-SCAN for short) is a clinical research study enrolling people age 65 to 80 who have normal cognition and a family history of Alzheimer’s disease dementia in a parent or sibling. The purpose of REVEAL-SCAN is to discover the best ways to communicate the results of brain scans and information about the risk of developing Alzheimer’s disease dementia by age 85.

All participants in the REVEAL-SCAN study will learn the results of two tests: 1) a brain scan that measures amyloid and 2) an individual risk estimate for developing Alzheimer’s disease dementia by age 85 based on their current age, race, gender, and family history. Participation involves no more than 7 visits over a 9-month period.

generation-study-logo_0

The Generation Study is a phase II/III clinical trial to test whether the drug CAD106 prevents Alzheimer’s disease. Cognitively normal individuals 60-75 years of age with an increased genetic risk of developing Alzheimer’s disease may be eligible. CAD106 is an investigational drug and is not FDA-approved.

Eligible participants will have two copies of the APOE 4 gene. If you do not know your genotype and are interested in learning more about how you may be eligible for the study, please visit the GeneMatch Study website at https://www.endalznow.org/genematch. GeneMatch is a research program of the Alzheimer’s Prevention Registry for people interested in participating in The Generation Study and other Alzheimer’s research studies based on their genetic information.

Mr_Pipo_thoughts.svg

The Biogen study is a Phase II clinical research study of the drug aducanumab for individuals age 50-85 with early Alzheimer’s disease, including mild cognitive impairment.

Aducanumab is a human antibody that recognizes some forms of beta-amyloid. The primary objective of the study is to evaluate the efficacy of aducanumab in slowing cognitive and functional impairment. This drug is not FDA-approved and is investigational.

Click here for a one-page handout on Biogen.

Welcome to Penn Memory Center

CiHbKbpWMAEUdD5

Aging and Cognition: Maintaining Economic Security in Later Life

On May 9 and 10, the World Economic Forum’s Global Agenda Council on Ageing (WEF GAC) and the University of Pennsylvania’s Healthy Brain Research Center were pleased to host “Aging and Cognition: Maintaining Economic Security in Later Life,” the fourth and final symposium in a series presented by the WEF GAC.

The symposia intended to increase action and impact on innovative approaches in the financial services sector to overcome limitations of age-related cognitive decline. Outcomes of each symposium will be shared through comprehensive reports, feedback, and recommended actions for engagement.

Click here to learn more about each symposia and watch videos of most Philadelphia presentations.


News and Events

The Memory Café returns Wednesday, December 21, 2016 with special guest Svitanya, a women’s vocal ensemble whose mission is to
Read More


A Penn Memory Center improv comedy workshop is setting the stage for a public performance Dec. 17 Improv Your Memory, formerly Cognitive
Read More


The Penn Memory Center and the Children’s Hospital of Philadelphia (CHOP) are teaming up for a program that pairs volunteers
Read More


  Join your neighbors Dec. 11 for a free, intergenerational discussion about and with the West Philadelphia community’s “keepers” of experiences.
Read More


  Penn Memory Center Co-Director Dr. Jason Karlawish has been appointed by Gov. Tom Wolf to serve on Pennsylvania Long-Term
Read More


Penn Memory Center in the Community

Click here to find out about the important work the Penn Memory Center is doing in the Philadelphia community.

 PMC in community

What does it mean to be a caregiver?

Click here to listen to the stories of caregivers from the PMC community.

I am a Caregiver

 

The University of Pennsylvania Prevention Research Center


The University of Pennsylvania Prevention Research Center seeks to advance public health goals, and serves as a hub for interdisciplinary chronic disease prevention research, training, and dissemination at the University of Pennsylvania.

Penn Memory Center's Jason Karlawish, MD, leads one of the PRC's Special Interest Projects - Alzheimer's/Dementia Assessment Messaging - and one of the SIP's Collaborating Networks - The Healthy Brain Research Center.

To read more about the PRC's work, visit their website at http://www.upennprc.org/